320 related articles for article (PubMed ID: 25139333)
1. Diagnostic and prognostic value of preoperative combined GFAP, IGFBP-2, and YKL-40 plasma levels in patients with glioblastoma.
Gállego Pérez-Larraya J; Paris S; Idbaih A; Dehais C; Laigle-Donadey F; Navarro S; Capelle L; Mokhtari K; Marie Y; Sanson M; Hoang-Xuan K; Delattre JY; Mallet A
Cancer; 2014 Dec; 120(24):3972-80. PubMed ID: 25139333
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic and prognostic value of stem cell factor plasma level in glioblastoma multiforme patients.
Kefayat A; Amouheidari A; Ghahremani F; Alirezaei Z
Cancer Med; 2021 Aug; 10(15):5154-5162. PubMed ID: 34250760
[TBL] [Abstract][Full Text] [Related]
3. Neuro-oncology: a step towards clinical blood biomarkers of glioblastoma.
Preusser M
Nat Rev Neurol; 2014 Dec; 10(12):681-2. PubMed ID: 25366110
[TBL] [Abstract][Full Text] [Related]
4. Prospective evaluation of serum glial fibrillary acidic protein (GFAP) as a diagnostic marker for glioblastoma.
Tichy J; Spechtmeyer S; Mittelbronn M; Hattingen E; Rieger J; Senft C; Foerch C
J Neurooncol; 2016 Jan; 126(2):361-9. PubMed ID: 26518540
[TBL] [Abstract][Full Text] [Related]
5. Serum YKL-40 following resection for cerebral glioblastoma.
Bernardi D; Padoan A; Ballin A; Sartori M; Manara R; Scienza R; Plebani M; Della Puppa A
J Neurooncol; 2012 Apr; 107(2):299-305. PubMed ID: 22102082
[TBL] [Abstract][Full Text] [Related]
6. Serum concentrations of glial fibrillary acidic protein (GFAP) do not indicate tumor recurrence in patients with glioblastoma.
Vietheer JM; Rieger J; Wagner M; Senft C; Tichy J; Foerch C
J Neurooncol; 2017 Oct; 135(1):193-199. PubMed ID: 28717884
[TBL] [Abstract][Full Text] [Related]
7. Serum GFAP is a diagnostic marker for glioblastoma multiforme.
Jung CS; Foerch C; Schänzer A; Heck A; Plate KH; Seifert V; Steinmetz H; Raabe A; Sitzer M
Brain; 2007 Dec; 130(Pt 12):3336-41. PubMed ID: 17998256
[TBL] [Abstract][Full Text] [Related]
8. Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas.
Lin Y; Jiang T; Zhou K; Xu L; Chen B; Li G; Qiu X; Jiang T; Zhang W; Song SW
Neuro Oncol; 2009 Oct; 11(5):468-76. PubMed ID: 19164435
[TBL] [Abstract][Full Text] [Related]
9. Investigation of serum levels and tissue expression of two genes IGFBP-2 and IGFBP-3 act as potential biomarker for predicting the progression and survival in patients with glioblastoma multiforme.
Abdolhoseinpour H; Mehrabi F; Shahraki K; Khoshnood RJ; Masoumi B; Yahaghi E; Goudarzi PK
J Neurol Sci; 2016 Jul; 366():202-206. PubMed ID: 27288807
[TBL] [Abstract][Full Text] [Related]
10. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas.
Hormigo A; Gu B; Karimi S; Riedel E; Panageas KS; Edgar MA; Tanwar MK; Rao JS; Fleisher M; DeAngelis LM; Holland EC
Clin Cancer Res; 2006 Oct; 12(19):5698-704. PubMed ID: 17020973
[TBL] [Abstract][Full Text] [Related]
11. Preoperative biomarkers of tumour vascularity are elevated in patients with glioblastoma multiforme.
Bennett IE; Guo H; Kountouri N; D'abaco GM; Hovens CM; Moffat BA; Desmond P; Drummond K; Kaye AH; Morokoff AP
J Clin Neurosci; 2015 Nov; 22(11):1802-8. PubMed ID: 26308396
[TBL] [Abstract][Full Text] [Related]
12. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma.
Tanwar MK; Gilbert MR; Holland EC
Cancer Res; 2002 Aug; 62(15):4364-8. PubMed ID: 12154041
[TBL] [Abstract][Full Text] [Related]
13. Plasma IGFBP-2 levels after postoperative combined radiotherapy and chemotherapy predict prognosis in elderly glioblastoma patients.
Han S; Meng L; Han S; Wang Y; Wu A
PLoS One; 2014; 9(4):e93791. PubMed ID: 24690948
[TBL] [Abstract][Full Text] [Related]
14. Exploratory investigation of eight circulating plasma markers in brain tumor patients.
Ilhan-Mutlu A; Wagner L; Widhalm G; Wöhrer A; Bartsch S; Czech T; Heinzl H; Leutmezer F; Prayer D; Marosi C; Base W; Preusser M
Neurosurg Rev; 2013 Jan; 36(1):45-55; discussion 55-6. PubMed ID: 22763625
[TBL] [Abstract][Full Text] [Related]
15. Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas.
Iwamoto FM; Hottinger AF; Karimi S; Riedel E; Dantis J; Jahdi M; Panageas KS; Lassman AB; Abrey LE; Fleisher M; DeAngelis LM; Holland EC; Hormigo A
Neuro Oncol; 2011 Nov; 13(11):1244-51. PubMed ID: 21831900
[TBL] [Abstract][Full Text] [Related]
16. Glial Fibrillary Acidic Protein in the Diagnosis and Prognosis of Malignant Glial Tumors.
Lyubimova NV; Timofeev YS; Mitrofanov AA; Bekyashev AK; Goncharova ZA; Kushlinskii NE
Bull Exp Biol Med; 2020 Feb; 168(4):503-506. PubMed ID: 32147765
[TBL] [Abstract][Full Text] [Related]
17. Elevated plasma YKL-40 as a prognostic indicator in patients with idiopathic pulmonary arterial hypertension.
Chen G; Yang T; Gu Q; Ni XH; Zhao ZH; Ye J; Meng XM; Liu ZH; He JG; Xiong CM
Respirology; 2014 May; 19(4):608-15. PubMed ID: 24689969
[TBL] [Abstract][Full Text] [Related]
18. YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas.
Nutt CL; Betensky RA; Brower MA; Batchelor TT; Louis DN; Stemmer-Rachamimov AO
Clin Cancer Res; 2005 Mar; 11(6):2258-64. PubMed ID: 15788675
[TBL] [Abstract][Full Text] [Related]
19. Serum biomarkers for glioblastoma multiforme.
Quddusi A; Shamim MS
J Pak Med Assoc; 2019 Jun; 69(6):913-914. PubMed ID: 31201406
[TBL] [Abstract][Full Text] [Related]
20. Platelet-derived growth factor receptor α/glial fibrillary acidic protein expressing peritumoral astrocytes associate with shorter median overall survival in glioblastoma patients.
Leiss L; Mega A; Olsson Bontell T; Nistér M; Smits A; Corvigno S; Rahman MA; Enger PØ; Miletic H; Östman A
Glia; 2020 May; 68(5):979-988. PubMed ID: 31769546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
